NOVT earnings call summary

Prepared Highlights

• Q4 2025: Record revenue with 9% reported growth, 2% organic growth, and 4% sequential growth; bookings surged 25% YoY and 12% sequentially; book-to-bill of 1.11 (CEO, CFO).
• FY 2025: Revenue of $981 million (record); full-year bookings grew 14%; new product sales grew over 60% YoY (CEO, CFO).
• Q4 Profit: Adjusted EBITDA grew 17% YoY to $61 million (23.5% margin); adjusted diluted EPS grew 20% YoY to $0.91 (CEO, CFO).
• FY Profit: Adjusted EPS of $3.29 (up 7% YoY); adjusted gross margin of 46% (CFO).
• Segment Q4: Medical Solutions revenue grew 16% YoY (book-to-bill 1.07); Automation Enabling Technologies revenue grew 2% YoY (book-to-bill 1.16) (CFO).
• Segment FY: Medical Solutions sales grew 5%; Automation Enabling Technologies sales grew 2% (CFO).
• Margins: Q4 adjusted gross margin 45.5% (down 150bps YoY) due to dual-running costs from manufacturing transfers; full-year 2026 margins expected to expand ~100bps to 47% (CEO, CFO).
• Cash Flow: Q4 operating cash flow $9M; FY 2025 operating cash flow $64M; FY 2026 guidance $145M–$185M (more than double 2025) (CFO).
• Capital Structure: Net debt negative $121M (positive net cash position for first time in over a decade); nearly $1.5B total acquisition capacity; $19M in Q4 share repurchases (CFO).
• Bookings: All four businesses delivered double-digit bookings growth and a positive book-to-bill in Q4 (first time since 2022) (CEO, CFO).

Official Guidance

• FY 2026 Revenue: $1,030M to $1,050M (4%–6% organic growth) (CFO).
• Q1 2026 Revenue: $250M to $255M (1%–3% organic growth) (CFO).
• FY 2026 Adjusted EBITDA: $245M to $250M (low double-digit YoY increase; ~24% margin) (CFO).
• Q1 2026 Adjusted EBITDA: $56M to $58M (12%–17% YoY growth) (CFO).
• FY 2026 Adjusted Diluted EPS: $3.50 to $3.65 (growth up to 11% YoY) (CFO).
• Q1 2026 Adjusted Diluted EPS: $0.75 to $0.80 (8% YoY growth) (CFO).

Mgmt Quotes

• "We said we would return to organic growth and double-digit profit growth in the fourth quarter, and we delivered." (CEO)
• "The setup here has never been stronger. Our teams have built the largest acquisition pipeline in my tenure as CEO, focused on mid to larger opportunities." (CEO)
• "Every single business delivered double-digit bookings growth, and a positive book-to-bill in the same quarter. That is the first time that has happened since 2022." (CEO)
• "Gross margins came in below our November guidance, a direct consequence of the decision... prioritizing customer deliveries over transfer timing." (CFO)
• "Acquisitions remain our top capital allocation priority, we will still repurchase shares... when the value of purchasing the stock gives us a greater cash return versus the intrinsic future value." (CFO)

Prepared Metrics

Q&A Batch (1–3 of 3)

Q1 — Lee M. Jagoda

• Topic: 自动化赋能技术板块订单增长驱动因素及工业机器人订单更新
• Key points:
  • 所有业务均实现双位数预订增长，且自2022年以来首次录得正向book-to-bill；AET板块中机器人与自动化、半导体资本设备及GPU电路板钻孔业务均获牵引
  • 精密制造业务连续四个季度实现双位数预订增长，Q4收入环比增长8%，预计2026年转为中个位数增长；谨慎去库存已消退，设计胜利逐步显现，激光束控制子系统新品类开始落地
  • 分业务book-to-bill：精密制造1.2（预订增长近50%，积压约1亿美元，为季度收入2倍）；机器人与自动化1.13（预订增长约25%，积压为季度收入1.5倍）；先进手术1.12（预订同比增长近15%，积压为季度收入2倍）；精密医学1.01（预订同比增长22%，积压为季度收入近2倍）
  • 工业机器人订单：第一阶段爬坡规模温和，随后将顺序加码；技术领导力产生光环效应
• Mgmt stance: 乐观，因为增长基础广泛、结构驱动因素明确，且企业正获得更多设计胜利和客户认可

Q2 — Brian Paul Drab

• Topic: 盈利增长指引与投资摊薄的调和，GPU电路板钻削业务细节
• Key points:
  • 2026年EPS中点预计同比增长约10%（非9%），但受融资摊薄约$0.22–$0.24及员工股权授予（仅上半年）约$0.14摊薄影响；有机EPS增速远高于10%
  • GPU电路板钻孔：公司是唯一能够钻孔极厚、极硬板材的供应商，该业务正快速上升，源于GPU领导者需求；客户为原有设备制造商（OEM），终端用户转向GPU领域；预计为多年增长轨迹
  • 所有四个业务单元（及两个分部）均实现正向book-to-bill
• Mgmt stance: 乐观，有机盈利增长强劲，GPU业务为独家领先地位且具备多年机遇

Q3 — Robert W. Mason

• Topic: 并购优先级（医疗导向、耗材、嵌入式软件）与财务筛选标准
• Key points:
  • 医疗收入占比已从10%增至约55%，方向将持续；